QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma
This is a single-center, open-label phase II study of QL1706 for the treatment of advanced bone and soft tissue sarcomas.The study includes screening period, treatment period and follow-up period. Subjects will receive QL1706 5mg/kg iv every 3 weeks until disease progression or intolerance. Efficacy should be evaluated and safety will be monitored throughout the study.
Bone and Soft Tissue Tumors
DRUG: QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
12 week PFS, The PFS rate at 12 weeks after the first injection assessed by the the investigator according to RECIST V1.1, From randomization to the first occurrence of disease progression or death from any cause, whichever occurs earlier, assessed at 12 weeks after first treatment
overall response rate (ORR), The ORR assessed by the investigator according to RECIST V1.1, Every 6 weeks, from the date of enrollment until the date of the last time that tumor imaging and assessment of disease has been done, assessed up to 2 years|The Disease Control Rate (DOR), The DOR assessed by the investigator according to RECIST V1.1, Every 6 weeks, from the date of enrollment until the date of the last time that tumor imaging and assessment of disease has been done, assessed up to 2 years
This is a single-center, open-label phase II study of QL1706 for the treatment of advanced bone and soft tissue sarcomas.The study includes screening period, treatment period and follow-up period. Subjects will receive QL1706 5mg/kg iv every 3 weeks until disease progression or intolerance. Efficacy should be evaluated and safety will be monitored throughout the study.